Radiographic changes are more common and severe in males with PsA. Over-weighting radiographic changes in your clinical reasoning will lead to missed diagnoses in women @lihi_eder @RheumNow #RNL2024 https://t.co/3OpMt7QaU8

Did you know?! Remission criteria perform differently in men and women with rheumatic diseases; studies really do NOT account for this. – Dr. Eder #RNL2024 @rheumnow https://t.co/2JOTyD1GDZ

Differences in presentation of PsA in men and women. Crucial to incorporate this into your diagnostic formulation @lihi_eder @RheumNow #RNL2024 https://t.co/uvnU1ujCX7

Picking the right tools to measure disease activity may be difficult because these tools may perform differently in men and women. The ASDAS show to differences between sexes but the BASDAI was significantly higher in women than in men. – Dr. Eder #RNL2024 @rheumnow https://t.co/KSBMrxio5P

Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR

Potential board question: be able to differentiate between osteitis condensan ilii vs sacroiliitis. With osteitis condensan, the SI joint is normal, with no irregularity, erosions, or loss of joint space. Sclerosis is predominantly on the iliac bone @rheumnow #RNL2024 @rheumnow https://t.co/mimcdoufEE

Men with PsA have more severe psoriasis, axial disease, high CRP, erosive disease compared to women, but women tend to have more pain. Delay to diagnosis in female patients are likely related to these differences- Dr. Eder #RNL2024 @rheumnow https://t.co/S9dzANITfH

Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX

Dr. Eder on gender differences – we need to move from gender blind to gender specific approach to treating our patients. There are biological, cultural, and social differences between males and females. #RNL2024 @rheumnow https://t.co/gnzU6FKIPR

Key takeaways when choosing therapies anti-TNFs, IL-17i, IL-23i, JAKs and TYK-2, in psoriasis. Think of skin, joint and spine involvement, April Armstrong #RNL2024 @RheumNow https://t.co/nUMmQk4xZq

Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC

#RNL2024 @RheumNow @_AprilArmstrong: Deucravacitinib v Apremilast Deucra: TYK2 inhibitor, approved for PsO (not yet PsA) Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum